Joint arthroplasty and infection: Where do we stand?

被引:0
|
作者
Vegari D.N. [1 ]
Parvizi J. [2 ]
机构
[1] Department of Orthopaedic Surgery, Thomas Jefferson University Hospital, Philadelphia, PA 19107
[2] Rothman Institute at Thomas Jefferson University Hospital, Philadelphia
关键词
Antibiotics; Cefazolin; Periprosthetic joint; Skin preparation; Space suits;
D O I
10.1615/JLongTermEffMedImplants.v21.i3.60
中图分类号
学科分类号
摘要
With the field of orthopedic surgery making tremendous advances, no one arena has changed more dramatically then total joint arthroplasty. While this kind of surgery has improved quality of life for many patients, it is not without complications. When they do occur, these complications can be devastating and inflict immense burden on patients and the society. Currently, the rate of periprosthetic joint infection ranges from 0.25% to 2.0%. As the number of total joint arthroplasty procedures is expected to rise considerably, these percentages will impose a financial burden on the field of adult reconstruction. The purpose of our paper is to discuss preventative measures that can be taken to curtail infections, the proper diagnosis of such infections, and the appropriate treatment options. © 2011 by Begell House, Inc.
引用
收藏
页码:225 / 232
页数:7
相关论文
共 50 条
  • [21] Rye and health - Where do we stand and where do we go?
    Jonsson, Karin
    Andersson, Roger
    Knudsen, Knud Erik Bach
    Hallmans, Goran
    Hanhineva, Kati
    Katina, Kati
    Kolehmainen, Marjukka
    Kyro, Cecilie
    Langton, Maud
    Nordlund, Emilia
    Laerke, Helle Nygaard
    Olsen, Anja
    Poutanen, Kajsa
    Tjonneland, Anne
    Landberg, Rikard
    TRENDS IN FOOD SCIENCE & TECHNOLOGY, 2018, 79 : 78 - 87
  • [22] Periprosthetic infection: where do we stand with regard to Gram stain?
    Ghanem, Elie
    Ketonis, Constantinos
    Restrepo, Camilo
    Joshi, Ashish
    Barrack, Robert
    Parvizi, Javad
    ACTA ORTHOPAEDICA, 2009, 80 (01) : 37 - 40
  • [23] Where do we stand in the OECD?
    Buske, L
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 1997, 156 (03) : 464 - 464
  • [24] Where do we stand with hepatoblastoma?
    Schnater, JM
    Köhler, SE
    Lamers, WH
    von Schweinitz, D
    Aronson, DC
    CANCER, 2003, 98 (04) : 668 - 678
  • [25] Inflation: Where do we stand?
    Martin, J
    INTERNATIONAL JOURNAL OF MODERN PHYSICS A, 2005, 20 (19): : 4676 - 4682
  • [26] GFIS - Where do we stand?
    Anon
    IUFRO News, 2002, 31 (02):
  • [27] The GSEs: Where do we stand?
    Poole, William
    FEDERAL RESERVE BANK OF ST LOUIS REVIEW, 2007, 89 (03): : 143 - 151
  • [28] Joint analysis of demography and selection in population genetics: where do we stand and where could we go?
    Li, Junrui
    Li, Haipeng
    Jakobsson, Mattias
    Li, Sen
    Sjodin, Per
    Lascoux, Martin
    MOLECULAR ECOLOGY, 2012, 21 (01) : 28 - 44
  • [29] VITILIGO - WHERE DO WE STAND
    ORTONNE, JP
    BOSE, SK
    PIGMENT CELL RESEARCH, 1993, 6 (02): : 61 - 72
  • [30] Where do we stand on econophysics?
    Carbone, A.
    Kaniadakis, G.
    Scarfone, A. M.
    PHYSICA A-STATISTICAL MECHANICS AND ITS APPLICATIONS, 2007, 382 (01) : XI - XIV